This document outlines key drug-drug interactions (DDIs) involving Duvyzat^® (givinostat), including contraindicated combinations, QTc prolongation risks, and metabolic pathway considerations.

Learn the story of Duvyzat^® (givinostat) and the significance of the EPIDYS trial. Hear neurologists describe key takeaways from the study, together with their thoughts on the potential impact on the DMD community.

View the Duvyzat^® Summary of Product Characteristics (SmPC) directly on the EMC website, where you can also download the latest version.

How does Duvyzat^® work for patients with DMD? This guide explains how this treatment works using simplified language and illustrations to answer patient and caregiver questions. This guide has been developed in collaboration with World Duchenne.

This is a resource to share with your patients, providing clear and concise instructions on the prescribed dosage of Duvyzat^®. Please utilise this dosing card in combination with the Patient Information Leaflet to support your patients and their caregivers to help follow their treatment plan effectively.

This Patient FAQ guide has been designed to answer common questions your patients and caregivers may have about Duvyzat^® and their treatment. We hope this guide provides you with the information you need to help patients and caregivers feel confident and informed about their treatment.